Further investigations are required to study whether the long-term outcomes of losing p53, such as compromised or defective DNA damage checkpoint, abnormal metabolism and low differential grade, which possibly make the survival of tumor cells more dependent on Plk1 function, are responsible for the cytotoxicity of Plk1 inhibition. This evidence concerns the gene PLK1 and neoplasm.